Clinical Features and Body Composition in Men with Hormone-Sensitive Metastatic Prostate Cancer: A Pilot Study Examining Differences by Race
Table 1
Clinical features in Black versus non-Black men with hormone-sensitive metastatic prostate cancerab.
Overall N = 74
Non-Black n = 51 (69%)
Black n = 23 (31%)
value
Age at diagnosis (yr), median (IQR)
71 (63–79)
71 (63–81)
70 (65–75)
0.9441
<65 yr, n (%)
23 (31)
16 (31)
7 (30)
1.000
≥65 yr, n (%)
51 (69)
35 (69)
16 (70)
Married, n (%)
43 (58)
33 (65)
10 (44)
0.2969
Insurance, n (%) (n = 73)
0.3203
Private
41 (56)
29 (58)
12 (52)
Public
31 (43)
21 (42)
10 (44)
Smoking status, n (%) (n = 72)
0.4024
Current
3 (4)
1 (2)
2 (9)
Former
40 (56)
28 (56)
12 (55)
Never
29 (40)
21 (42)
8 (36)
Body mass index (kg/m2), median (IQR) (n = 71)
27.6 (24.8–31.1)
28.3 (25.2–31.0)
26.3 (22.5–32.8)
0.5907
ECOG at diagnosis, n (%)
0.0589
0
59 (80)
44 (86)
15 (65)
≥1
15 (20)
7 (14)
8 (35)
Baseline PSA (ng/mL), median (IQR) (n = 51)
110 (35–677)
81 (22–403)
304 (53–1402)
Gleason score, n (%)
0.1736
7
27 (36)
16 (31)
11 (48)
8–10
47 (64)
35 (69)
12 (52)
Total distant metastases, median (IQR)
1 (1-2)
1 (1-2)
2 (1-2)
0.8065
Bone metastases, n (%)
56 (76)
39 (76)
17 (74)
1.000
Laboratory values, median (IQR)
Hemoglobin (g/dL) (n = 71)
12.5 (11.0–13.69)
13.0 (11.5–13.9)
11.1 (8.6–13.7)
0.0408
Lymphocytes (109 cells/liter) (n = 65)
1.4 (1.0–1.8)
1.3 (1.0–1.8)
1.6 (1.2–1.8)
0.5270
Creatinine (mg/dL) (n = 73)
(1.10.05)(0.9–1.6)
1.1 (0.9–1.4)
1.5 (1.1–1.7)
0.0454
ALT (U/L) (n = 70)
21 (15–27)
21 (15–29)
18 (15–22)
0.2722
ALP (U/L) (n = 70)
95 (68–229)
89 (65–216)
117 (73–412)
0.4456
Albumin (g/dL) (n = 70)
3.6 (3.4–4.1)
3.7 (3.5–4.2)
3.4 (3.1–3.6)
0.0055
Comorbid conditions, median (IQR)
2 (1–3)
2 (1–3)
2 (2-3)
0.4455
History of diabetes, n (%)
21 (28)
11 (22)
10 (43)
0.0530
Presenting symptoms, n (%)
None
7 (9)
7 (14)
0 (0)
0.0912
Fatigue
11 (15)
6 (12)
5 (22)
0.3008
Hematuria
18 (24)
12 (23)
6 (26)
0.8124
Lower urinary tract
45 (61)
32 (63)
13 (57)
0.6118
Pain
28 (38)
18 (35)
10 (43)
0.5017
Weight loss
21 (28)
11 (22)
10 (43)
0.0530
Frontline docetaxel, n (%)
25 (34)
18 (35)
6 (26)
0.4336
Progression, n (%) (n = 62)c
34 (55)
26 (60)
8 (44)
0.2928
Died, n (%) (n = 66)
36 (55)
26 (56)
10 (50)
0.6248
aALT = alanine aminotransferase, ALP = alkaline phosphatase, ECOG = European Cooperative Oncology Group; IQR = interquartile range, and PSA = prostate-specific antigen. bMedian follow-up for all patients 23.3 (13.4–35.0), Black 18.9 (11.8–36.5), and non-Black 24.7 (14.6–35.0) in months. cSample less than 74 as progression status was unknown for 12 men.
